Potentiation of antitumor effect of NKT cell ligand, α-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells

Clinical and Experimental Metastasis

Volumn 18, Issue 2, 2000, Pages 147-153

  Nakui, Minoru ^a   Ohta, Akio ^a   Sekimoto, Masashi ^a   Sato, Marimo ^a   Iwakabe, Kenji ^a   Yahata, Takashi ^a   Kitamura, Hidemitsu ^a   Koda, Toshiaki ^b   Kawano, Tetsu ^c   Makuuchi, Hiroyasu ^d   Taniguchi, Masaru ^c   Nishimura, Takashi ^a  

^a Section of Genetic Engineering   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

galactosylceramide; IL 12; Immunotherapy; NKT cells; Tumor metastasis

Indexed keywords

GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LIGAND BINDING; LUNG METASTASIS; MELANOMA; NATURAL KILLER CELL; TUMOR CELL CULTURE;

ANIMALS; DRUG SYNERGISM; GALACTOSYLCERAMIDES; INTERLEUKIN-12; LIGANDS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

EID: 0035112622     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006715221088     Document Type: Article

References (38)

1. + T-cell antigen receptor α chain expanded in unprimed mice
2. A novel population of T-cell receptor αβ-bearing thymocytes which predominantly express a single Vβ gene family
3. + cells in mouse liver
4. - single-positive thymocyte subpopulation that expresses a highly skewed T-cell antigen receptor Vβ family
5. Mouse CD1-specific NK1 T cells: Development, specificity and function
6. A novel cell type responsible for bone marrow graft regection in mice, T cell with NK phenotype cause acute rejection of bone marrow grafts
7. + subset
8. + cells in the liver of mice
9. + cells
10. + thymocytes
11. + T lymphocytes
12. -α/β T cells demonstrates preferential use of several Vβ genes and an invariant TCR α chain
13. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides
14. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand
15. The natural killer T (NKT) cell ligand a-Galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
16. Activation of NKT cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype
17. Immunization with α-galactosylceramide polarizes CD1-reactive NKT cells towards Th2 cytokine synthesis
18. Natural killer T cell ligand α-galactosylceramide inhibited lymph node metastasis of highly metastatic melamoma cells
19. KRN7000, a novel immunomodulator, and its antitumor activities
20. Antitumor activities of combined treatment with a novel immunomodulator, (2S,3S,4R)-1-O-(α-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4- octadecanetriol (KRN7000), and radiotherapy in tumor-bearing mice
21. - T cells in non-MHC gene-controlled predisposition toward skewing into T helper type-2 immunity in BALB/c mice
22. + cells
23. Protein kinase C required for cytotoxic T lymphocyte triggering
24. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells
25. Natural killer like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells
26. + αβ T cells with intermediate TCR induced in the liver of mice by IL-12
27. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer
28. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids
29. Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2
30. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12
31. Treatment of Hepatic metastasis of Colon26 adenocarcinoma with an α-galactosylceramide, KRN7000
32. + T cells in IL-12-induced immune responses in vivo
33. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors
34. The expanding universe of T-cell subsets: Th1, Th2 and more
35. + T cells secreting Th1 and Th2 cytokines
36. Functional skewing of bone marrow-derived dendritic cells by Th1- or Th2-inducing cytokines
37. The interface between innate and aquired immunity. Glycolipid antigen presentation by CD1d-expressing dendritic cells to natural killer T cells induces the differenciation of antigen-specific cytotoxic T lymphocytes
38. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo